(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Exercises to Anticipate in 2024 - 2Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- 3Instructions to Guarantee Kids Foster Solid Dental Propensities
- 4Sought-After Extravagance Ocean side Objections for a Lovely Escape
- 5Finding the Force of Mentorship: Self-awareness Through Direction
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Manual for 6 famous sorts of cheddar
- Wedding trip Objections in the US
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- Vote In favor of Your Number one Cell phones
- Home Mechanization Frameworks for Brilliant Residing
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- Without evidence, CDC changes messaging on vaccines and autism
- CDC website changes to include false claim about autism and vaccines
